Commentary on pravastatin and cancer: Need for individual patient data meta-analyses

Pharmacoepidemiology and Drug Safety

Volumn 19, Issue 2, 2010, Pages 203-204

  Bonovas, Stefanos ^a,b   Nikolopoulos, Georgios ^b   Sitaras, Nikolaos M ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b Hellenic Centre for Disease Control and Prevention   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

PRAVASTATIN;

CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; DRUG EFFECT; DRUG UTILIZATION; GROUPS BY AGE; HUMAN; JAPANESE; LETTER; PATIENT CODING; PRIORITY JOURNAL; THERAPY EFFECT;

ANTICHOLESTEREMIC AGENTS; CONTROLLED CLINICAL TRIALS AS TOPIC; HUMANS; JAPAN; META-ANALYSIS AS TOPIC; MIDDLE AGED; NEOPLASMS; PRAVASTATIN; REFERENCE STANDARDS;

EID: 76149098847     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1910     Document Type: Letter

References (6)

1. Matsushita Y, Sugihara M, Kaburagi J, et al. Pravastatin use and cancer risk: a meta-analysis of individual patient data from long-term prospective controlled trials in Japan. Pharmacoepidemiol Drug Saf 2009 [E-pub ahead of print: DOI 10.1002/pds.1870].
2. Bonovas S, Sitaras NM. Does pravastatin promote cancer in elderly patients? A meta-analysis. CMAJ 2007; 176: 649-654.
3. Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine: reporting of subgroup analyses in clinical trials. N Engl J Med 2007; 357: 2189-2194.
4. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ 2003; 326: 219.
5. Trialists' (CTT) Collaboration. Protocol for a prospective collaborative overview of all current and planned randomized trials of cholesterol treatment regimens. Am J Cardiol 1995; 75: 1130-1134.
6. Pfeffer MA, Keech A, Sacks FM, et al. Safety and tolerability of pravastatin in long-term clinical trials: prospective pravastatin pooling (PPP) project. Circulation 2002; 105: 2341-2346.